SeHCAT improves confidence of treatment selected

SeHCAT test gives an objective diagnosis of BAD enabling clinicians to confidently treat with bile acid sequestrant.^1,2

Bile acid sequestrants (BAS) such as cholestyramine have been shown to be effective in treating diarrhoea secondary to bile acid malabsorption, with up to 96% of D-IBS patients diagnosed with BAM responding.³

Therapeutic options for Bile Acid Diarrhoea

Cholestyramine is typically used first-line to treat people diagnosed with BAD. Approximately 50% of people prescribed cholestyramine will continue with this treatment long term.⁴
For those who cannot tolerate cholestyramine, some gastroenterologists treat BAD with newer BAS treatments, like colesevelam. It is typically better tolerated⁴, however, this use is not licensed in the UK yet.
Modification of diet has been also suggested as a treatment option, especially for patients with BAD after cancer therapy. The fat reduction can improve symptoms, making it an important therapeutical option.⁵

References:
1. Smith MJ et al. J R Coll Physicians Lond 2000; 34 (5): 448-51.
2. Basumani et al. Gut 2008; 57 (Suppl I): A1-A172.
3. Wedlake L et al. Aliment Pharmacol Ther 2009; 30 (7): 707-17.
4. NICE diagnostics guidance [DG7] 2012.
5. Gupta A et al. Support Care Cancer 2015 1-10.

JB7345C 10-2017